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Antimicrobial susceptibility testing (AST) of clinical isolates is
essential for guiding therapy as well as for surveillance of antimi-
crobial resistance (AMR). The two most commonly used method-
ologies worldwide are those of the Clinical and Laboratory
Standards Institute (CLSI) and the European Committee for Anti-
microbial Susceptibility Testing (EUCAST). CLSI predominates in the
United States and many regions outside Europe, where EUCAST is
preferred. However, the global situation is evolving, with countries
such as Australia recently switching to EUCAST [1]. The choice of
AST methodology assumes increasing importance given the
growing international focus on AMR, with both systems recom-
mended in the World Health Organization's Global Antimicrobial
Resistance Surveillance System (GLASS) [2]. Although collaboration
between CLSI and EUCAST has occurred, fundamental differences
have so far precluded them from merging or harmonizing break-
points [3].
The MahidoleOxford Tropical Health Network (MORU) includes
laboratories in Thailand, Laos and Cambodia that currently use CLSI
disk-diffusion AST guidelines for both routine diagnostic and
research purposes, but have recently been considering switching to
EUCAST. Key perceived beneﬁts of EUCAST include the stringency
and transparency of EUCAST breakpoint-setting processes evident
in detailed rationale documents, the lack of formal industry rep-
resentation on EUCAST committees, and the freely available nature
of all output in user-friendly format. Updated CLSI documents must
be purchased annually, at a cost to non-members in 2018 of
US$342e504 depending on the bundle chosen, although break-
points for frequently isolated non-fastidious organisms can be
freely accessed as an online-only companion to the CLSI M100
document [4].While studies have examined the impact of replacing
CLSI with EUCAST breakpoints, published reports of the practical
laboratory implications of switching between the two methodol-
ogies are lacking, particularly for low- and middle-income coun-
tries. We report here the key practical differences between CLSI and
EUCAST methodologies and the implications of adopting EUCAST
guidelines in our laboratory network.
Clinical breakpoints from both organizations from 2018 [5,6]
and disk-diffusion AST guidelines from 2018 from CLSI [7] and
from 2017 from EUCAST [8,9] were assessed for signiﬁcant differ-
ences. We also examined the impact of discrepancies in CLSI and
EUCAST zone diameter breakpoints on the interpretation of anti-
microbial susceptibility of frequently isolated Gram-negative or-
ganisms at one of our sitesdthe Mahosot Microbiology Laboratory,
Vientiane, Laosdin 2017, as reported in this issue of CMI [10].
Although a formal cost analysis was not performed, major addi-
tional expenses or savings associated with adopting EUCAST were
estimated where possible. Finally, in order to place our ﬁndings in a
global context, a literature search was performed for articles
reporting on EUCAST implementation or differences between
EUCAST and CLSI (see web-only Supplementary Fig. S1 and
Supplementary Table S1).
Recommendations for inoculum preparation, agar inoculation,
disk application and zone diameter reading are similar. Key
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practical differences are summarized in Table 1. EUCAST recom-
mends an incubation temperature of 35 ± 1C for 16e20 h for AST
of all organisms except Campylobacter spp. and when testing gly-
copeptides against Enterococcus spp., which require 24 h in both
methodologies. CLSI incubation durations are more variable, and
the recommended temperature is 35 ± 2C. Both systems use
MuellereHinton agar (MHA) for AST of Enterobacteriaceae, Pseu-
domonas spp., Staphylococcus spp., Acinetobacter spp., and Entero-
coccus spp., but CLSI uses sheep blood for MHA supplementation
whereas EUCAST uses horse blood. Discordant disk contents are
used for 13 antimicrobial agents.
Comparison of published zone diameter breakpoints revealed
important differences. CLSI provides zone diameter breakpoints for
Neisseria gonorrhoeae and N. meningitidis, whereas EUCAST has so
far deemed disk diffusion unreliable for these organisms and pro-
vides only MIC criteria. Within EUCAST breakpoints for Entero-
bacteriaceae there are no zone diameter criteria for
azithromycineSalmonella Typhi, and the nitrofurantoin breakpoint
applies only to urinary Escherichia coli with the justiﬁcation that
other members of the Enterobacteriaceae are more likely to cause
complicated or upper urinary tract infections for which nitro-
furantoin is inappropriate. Breakpoints are rarely aligned between
the two systems, and the proportion containing an intermediate
category is markedly higher in CLSI guidelines. Using the Entero-
bacteriaceae as an example, 64/69 (93%) of CLSI breakpoints
included an intermediate category compared to 24/48 (50%) with
EUCAST, and EUCAST resistance cut-offs were higher in 26/33
directly comparable zone diameter breakpoints. Our susceptibility
interpretation comparison [10] demonstrated that these discrep-
ancies would have signiﬁcantly increased reported co-amoxiclav
and ciproﬂoxacin resistance rates amongst clinical isolates of
E. coli and Klebsiella pneumoniae had EUCAST 2018 breakpoints
been used. It must be noted that from 1st January 2019, EUCAST
changed its deﬁnition of the intermediate category to ‘Susceptible,
increased exposure’ [11] for when there is a high likelihood of
therapeutic success because exposure to the agent is increased by
adjusting the dosing regimen or by its concentration at the site of
infection. As well as providing unequivocal interpretation of this
category, this aims to extend the range of therapeutic options in an
era of increasing AMR. The previous deﬁnition was more aligned
with that of the CLSI as an area of uncertain therapeutic efﬁcacy
that included a buffer zone to allow for uncontrolled technical
variation. Reporting of results in laboratories adopting EUCAST
breakpoints will therefore need to reﬂect the new deﬁnition,
requiring additional engagement with laboratory users.
Routine quality control recommendations for disk-diffusion AST
are broadly similar. Both organizations advocate daily quality
control testing of antimicrobial agents that form part of routine
panels, although CLSI allows weekly testing if results on a sufﬁcient
number of consecutive days are within range. The same American
Type Culture Collection (ATCC) strains of E. coli, Pseudomonas aer-
uginosa, Enterococcus faecalis, Streptococcus pneumoniae, and
Table 1
Key differences between the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial Susceptibility Testing (EUCAST) disk diffusion
methodologies
Methodological discrepancy CLSI EUCAST
Incubation temperature 35 ± 2C 35 ± 1C
Duration of incubation 16e18 h for Enterobacteriaceae, Staphylococcus spp.a and
Pseudomonas
aeruginosa; 20e24 h for most other organisms
16e20 h
Media MHA supplemented with 5% sheep blood for Streptococcus spp.,
Campylobacter jejuni/coli, Pasteurella spp. and Neisseria
meningitidis;
Haemophilus
Test Medium for Haemophilus spp.; GC agar base
with 1% deﬁned growth supplement for Neisseria gonorrhoeae
MH-F agar for Streptococcus spp.,
Campylobacter
jejuni/coli, Pasteurella spp., H. inﬂuenzae,
Moraxella
catarrhalis, Listeria monocytogenes,
Kingella kingae,
Aerococcus
spp. and Corynebacterium spp.
Antimicrobial disk contents
(mg unless otherwise stated)
Amoxicillineclavulanic
acid
20e10 20e10 and 2e1b
Ampicillin 10 10 and 2c
Cefotaxime 30 5
Ceftaroline 30 5
Ceftazidime 30 10
Ceftazidimeeavibactam 30e20 10e4
Gentamicind 120 30
Linezolid 30 10
Nitrofurantoin 300 100
Penicillin G 10 units 1 unit
Piperacillin 100 30
Piperacillinetazobactam 100e10 30e6
Vancomycin 30 5
Zone diameter breakpoints None for Aerococcus spp., Kingella kingae, Listeria
monocytogenes,
Corynebacterium spp.
Rarely aligned with EUCAST
None for N. gonorrhoeae, N.
meningitidis, Burkholderia
cepacia, Vibrio spp.
Fewer intermediate categories
ATCC strains for routine disk diffusion quality control Staphylococcus aureus ATCC 25923,
H. inﬂuenzae ATCC 49247
S. aureus ATCC 29213,
H. inﬂuenzae ATCC 49766
MHA, MuellereHinton agar; MH-F agar, MHA supplemented with 5% horse blood and 20 mg/L b-NAD.
a Except when testing cefoxitin against coagulase-negative staphylococci which requires 24 h.
b For testing H. inﬂuenzae, Pasteurella multocida, Moraxella catarrhalis, and Listeria monocytogenes.
c For testing H. inﬂuenzae, viridans group streptococci, Staphylococcus saprophyticus and Enterococcus spp.
d For testing high-level resistance in Enterococcus spp.
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Campylobacter jejuni are employed by both systems, but different
ATCC strains of Staphylococcus aureus and Haemophilus inﬂuenzae
are used.
Two signiﬁcant cost implications of switching to EUCAST were
identiﬁed. Losing the requirement to purchase CLSI documents
annually could save approximately US$342e504 per year. However,
lack of EUCAST zone diameter breakpoints would require the
introduction of a commercial MIC methodde.g. Etest (bioMerieux,
France)dfor the AST of N. gonorrhoeae. At the Mahosot Microbi-
ology Laboratory, where 82 N. gonorrhoeae isolates underwent
disk-diffusion AST in 2017 against ﬁve antimicrobial agents, the
added cost of using Etests for these same agents would have been
approximately US$1200.
Difﬁculties in acquiring quality-assured horse blood in South-
east Asia pose a signiﬁcant barrier to adopting EUCAST media re-
quirements for AST of fastidious organisms. As is common practice
in resource-constrained settings, our laboratories in Laos and
Cambodia prepare agar plates on site, relying on local sources of
goat and sheep blood respectively. It is not currently feasible to
obtain horse blood or to import pre-poured plates in these coun-
tries, and only MHA supplemented with 5% sheep blood is available
from our commercial supplier in Thailand (Clinical Diagnostics Ltd,
Bangkok, Thailand). Goat blood is used at Mahosot Microbiology
Laboratory as it has been shown to be a reasonable substitute for
sheep blood [12], which is unavailable in Laos. Another common
source of blood for media supplementation in low-income coun-
tries is expired banked human blood, which is suboptimal for the
isolation and ASTof fastidious organisms [13]. As many laboratories
purporting to follow CLSI guidelines will be using more accessible
alternatives to sheep blood, challenges in adhering to media
guidelines in resource-constrained settings are not unique to
EUCAST. Practical solutions are required, and to this end EUCAST is
exploring the use of freeze-dried horse blood as a supplement for
locally prepared media (G. Kahlmeter, personal communication
2017).
Our literature search (see web-only Supplementary Fig. S1 and
Supplementary Table S1) identiﬁed 101 articles in PubMed
reporting on EUCAST implementation (n ¼ 8), speciﬁc methodo-
logical discrepancies between CLSI and EUCAST (n ¼ 20), and
comparisons of CLSI and EUCAST breakpoints for susceptibility
interpretation (n ¼ 73). The susceptibility comparisons generally
reported higher resistance rates with EUCAST breakpoints, which
our own ﬁndings supported [10], and all articles about EUCAST
implementation were from Europe, focusing mainly on the history
and structure of EUCAST, organizational differences with CLSI, and
EUCAST breakpoint-setting and disk-diffusion methodologies. One
recent article [14] proposes a roadmap for transitioning from CLSI
to EUCAST in Spanish laboratories, providing useful general rec-
ommendations and highlighting differences between CLSI and
EUCAST such as antimicrobial disk contents and media. However,
its broader utility may be limited as it is speciﬁcally orientated
towards Spanish laboratories and is available only in Spanish.
Although we found no articles discussing EUCAST implementation
in low- and middle-income countries, we anticipate difﬁculties
with meeting EUCAST standards for blood-supplemented media
and AST of N. gonorrhoeae to be broadly applicable across resource-
constrained settings.
Despite compelling reasons to adopt EUCAST AST guidelines,
following discussion at network meetings in 2017 and early in 2018
the consensus decision amongst MORU clinical microbiologists was
not to do so at the time. The main reasons behind this were the
absence of a national push to change and the need to keep our data
comparable with those of other laboratories in the countries in
which we work, highlighting another potential barrier to EUCAST
implementation outside of Europe. While EUCAST implementation
in Europe was driven and coordinated by well-established national
committees, it may be challenging for individual laboratories in
other regions to switch from CLSI to EUCASTwithout a uniﬁed drive
to change at the national level. During the preparation of this
manuscript there has been renewed interest in adopting EUCAST
methodology in Laos, and a switch from CLSI to EUCAST is planned
at Mahosot Microbiology Laboratory and nationally during 2019,
albeit with continued use of local sources of blood for media sup-
plementation and retention of CLSI disk diffusion standards for AST
of N. gonorrhoeae. Our laboratories in Thailand and Cambodia will
continue with CLSI.
In conclusion, there are important practical differences between
CLSI and EUCAST disk-diffusion ASTguidelines, andwhilst we agree
with other authors advocating EUCAST as the preferred AST
methodology in low- andmiddle-income countries [15], challenges
involved in switching to EUCAST from CLSI should not be under-
estimated in these settings. Furthermore, discrepancies in clinical
breakpoints will alter institutional antibiograms following a switch
between the two methodologies, and will hamper broader AMR
surveillance initiatives such as GLASS. This report highlights the
need for a globally harmonized AST system that is practical and
freely available, and we hope it will be a useful guide for labora-
tories considering switching between CLSI and EUCAST.
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